Dyne Therapeutics (DYN) stock

Muscle disease therapeutics , market cap $3.2B

Therapeutics for genetic muscle diseases

Worth $3.2B

$17.92

-3.76%

FDA in 72 daysEvery upcoming FDA date ›

As of Tuesday's close · Live for Pro members at the open

Why is DYN down?

Down 3.8% today, more than its biotech peers' 1.4%; no story names it yet.

Fell on Nov 5

Down 6.4% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%.

Its Nov 5 results: net loss per share, basic and diluted widened to $1.06, from $0.76 a year before. It fell 6% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

Tell me next time DYN moves

Free account, no card. An optional alert when DYN moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

-6

Poor

In its industry

#218of 281

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-34.4%

under its best in a year

DYN's Quality Score fell 3 points on Tue, Nov 10, to -6. Buying slipped from its highest in 20 days (3 chart checks stopped).

Follow DYN's trial news. Pro members can get an alert when Dyne Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DYN files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextJan 21, 2027 · In 72 days“…Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027…”FDA decision date · SEC filing · Nov 5

Cash$1.1B, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into the second quarter of 2028”

Key facts on DYN

Key facts on DYN
Holding it back	28.2% more shares than a year ago from Massive's market data
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind DYN's -6, free with an account →3 more reasons behind DYN's -6, for Pro members.

DYN in the news

TodayNo story names it yet.

Cash$1.1B, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into the second quarter of 2028”

DYN catalysts

Coming up

After its last 4 reports it closed +1.1% on average, higher 3 of 4 times.

5 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for DYN, and how long its cash lasts

Next step the company has named

Jan 21, 2027In 72 days“- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -”FDA decision date · SEC filing · Nov 5

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

Cash runway Sep 30 balance sheet

About 8 quarters

$1.1B in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the second quarter of 2028” (8-K, Nov 5).

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 5, 2024)
At-the-market share sales program (424B5, filed Nov 12, 2024)

For Pro members: 6 raises and their amounts, and the share count against a year ago.

Insiders

Director Brian S. Posner bought 2,500 shares on Oct 2. 42 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when John Cox buys or sells

For Pro members: every trade, and John Cox’s 19 filings and quotes.

Get an alert before DYN's FDA date

A free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why DYN scores -6

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

-6 is below -5, off the left end of the scale.

−2Long-term trend below a falling 200-⁠day average, down over two years
−2Dilution 28.2% more shares outstanding than a year ago, from Massive's market dataNew shares over the year: -1 at 10% more, -2 at 25% more.

Chart checks adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on DYN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:01 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How DYN ranks in Biotech

DYN is #218 of 281 by Quality Score.

How DYN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	DSGNDesign Therapeutics		Open for its score
	DTILPrecision BioSciences		Open for its score
	EBSEmergent Biosolutions		Open for its score
	EDITEditas Medicine		Open for its score
218	DYNDyne Therapeutics	1/14	-6

Net income over four quarters: DYN -$605M, ARWR -$320M, CYTK -$778M.

When does DYN report earnings, and what happens after?

Expected to report Mon Mar 1, before the open (in 111 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DYN reported on Nov 5, 2026

The quarter

A loss of $1.06 a share, from $0.76.

“The increase in R&D expense was primarily due to increased manufacturing activity for z-rostudirsen and higher clinical trial costs related to conducting the ongoing FORZETTO and HARMONIA Phase 3 trials for z-rostudirsen and z-basivarsen, respectively.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

DYN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase in G&A expenses was primarily due to preparation for the potential launch of z-rostudirsen, including an increase in headcount.”

From its results filing (SEC filing · Nov 5)

1 more sentence, for Pro members.

The numbers

Market value: $3.2B; today
Free cash flow: -$569M; last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DYN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+4.8%+2.5%-6.4%

May 11Jul 29Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	+1.3%	-6.4%	not yet
Jul 29, 2026After close	After close	-2.4%	+2.5%	+4.3%
May 11, 2026Before open	Before open	-0.3%	+4.8%	-1.8%

DYN closed higher after 3 of its last 4 reports.

All 4 reports, and DYN's Quality Score going into each

DYN has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on DYN, and all 14 on every stock.Get in free →

DYN RSI today: 54.8, above its 50-day, below its 200-day

Not scored

RSI 54.8, MACD above signal, above its 50-day, below its 200-day. Not scored.13 readings

The deep dive on DYN

What it does and how it makes money2 findingsFor Pro members2 findings on what DYN does and how it makes money, for Pro members
Where it stands3 findingsIt spent $569M more than its operations brought in over the four quarters to Sep 30, 2026, after capital spending.Cash flow statements to Sep 30, 2026, filed Nov 5, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades DYN, for Pro members
Against its closest peers2 peersNet income over four quarters: DYN -$605M, ARWR -$320M, CYTK -$778M.

6 more findings on DYN, each with its source, for Pro members.

DYN share count over time

Shares of DYN outstanding, as filed
Shares outstanding	As of
187.4M	Oct 30, 2026
186.7M	Jul 24, 2026
142.8M	Oct 31, 2025
142.3M	Jul 25, 2025

Offerings, shelves, and splits of DYN, from its filings
From its filings	Filed
Raised $375.1M in a sale of shares, about 12% of its market value	Jul 22, 2026
Raised $350M in a sale of shares, about 11% of its market value	Dec 10, 2025
Raised $200M in a sale of shares, about 6% of its market value	Jul 1, 2025
Set up an at-the-market program for up to $300M of shares, about 9% of its market value	Nov 12, 2024

3 more offerings on file, for Pro members.

DYN insider trades

One insider bought $197K across 5 filings, and one insider sold $48K across 1 filing, in the last 6 months. The newest:

BuyBrian S. Posner$40KDirectorat $16.00 on Oct 2, filed Oct 6

BuyBrian S. PosnerDirector$40Kat $16.00 on Oct 2, filed Oct 6

All 6 insider filings on DYN from the last six months, for Pro members.

All DYN insider trades

DYN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

John CoxCEO & President · 6 trades
Erick LuceraChief Financial Officer · 4 trades
Douglas KerrHead of R&D and CMO · 7 trades
Johanna Friedl-NadererChief Commercial Officer · 7 trades
Jason P. RhodesDirector · 19 trades
Dirk KerstenDirector · 14 trades
Brian S. PosnerDirector · 6 trades
David Charles LubnerDirector · no trades on file

See insider trades by person

Which ETFs hold DYN?

In ETFs: DYN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

258 employeesWaltham, MAdyne-tx.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on DYN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn DYN's score around: 8 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 6Brian S. Posner bought DYN$40K at $16.00, filed Oct 6

Alerts are optional.

See DYN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: DYN's Quality Score is -6 (Poor), #218 of 281 in Biotech. Insiders bought $197K and sold $48K in the last 6 months (Form 4).

What does DYN's Quality Score say?

DYN scores -6 today, which Breakaway calls Poor. It is #218 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 6.4% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DYN's Quality Score?

DYN scores -6 today, which Breakaway calls Poor (below zero). That is #218 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DYN's -6.

Are insiders buying DYN?

One insider bought $197K across 5 filings, and one insider sold $48K across 1 filing, in the last 6 months. The newest is Brian S. Posner, Director, who bought $40K on Oct 2. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.